- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04809363
Une étude de CDPATH™ pour aider à gérer et à traiter la maladie de Crohn (COMPASS-CD)
Une étude de phase 4 évaluant l'utilisation réelle de CDPATH™, un outil de prédiction du risque de maladie de Crohn
CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The tool being tested in this study is called CDPATH™. CDPATH™ is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH™.
The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH™ process and with their treatment choice.
This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85032
- Arizona Arthritis & Rheumatology Research, PLLC
-
-
California
-
Loma Linda, California, États-Unis, 92357
- VA Loma Linda Healthcare System
-
Murrieta, California, États-Unis, 92563
- United Medical Doctors
-
Newport Beach, California, États-Unis, 92663
- University of Southern California Medical Center
-
Orange, California, États-Unis, 92868
- University of California at Irvine Medical Center
-
Orange, California, États-Unis, 92868
- Clinnova Research Solutions
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80014
- Kaiser Permanate of Colorado
-
-
Connecticut
-
Hamden, Connecticut, États-Unis, 06518
- Medical Research Center of Connecticut, LLC
-
-
Florida
-
Clearwater, Florida, États-Unis, 33762
- West Central Gastroenterology d/b/a Gastro Florida
-
Pensacola, Florida, États-Unis, 32503
- Gastroenterology Associates of Pensacola, PA
-
-
Idaho
-
Idaho Falls, Idaho, États-Unis, 83404
- Grand Teton Research Group, PLL
-
-
Illinois
-
Arlington Heights, Illinois, États-Unis, 60005
- GI Alliance
-
Gurnee, Illinois, États-Unis, 60031
- GI Alliance
-
Northbrook, Illinois, États-Unis, 60062
- Comprehensive Gastrointestinal Health
-
Rockford, Illinois, États-Unis, 61107
- Rockford Gastroenterology Associates, Ltd.
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Indiana University
-
-
Iowa
-
Clive, Iowa, États-Unis, 50325
- Iowa Digestive Disease Center
-
Iowa City, Iowa, États-Unis, 52242-1009
- University of Iowa Hospitals & Clinics
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160
- University of Kansas Medical Center Research Institute, Inc.
-
-
Louisiana
-
Baton Rouge, Louisiana, États-Unis, 70809
- GI Alliance - Baton Rouge
-
Shreveport, Louisiana, États-Unis, 71105
- Louisiana Research Center, LLC
-
-
Maryland
-
Columbia, Maryland, États-Unis, 21045
- Gastro Center of Maryland
-
-
Massachusetts
-
Burlington, Massachusetts, États-Unis, 01805
- Lahey Clinic Inc. - PARENT ACCOUNT
-
Worcester, Massachusetts, États-Unis, 01655
- UMASS Memorial Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87131-0001
- University of New Mexico
-
-
New York
-
New York, New York, États-Unis, 10075-1850
- Lenox Hill Hospital
-
-
Ohio
-
Beavercreek, Ohio, États-Unis, 45431
- Clinical Inquest Center Ltd
-
Dayton, Ohio, États-Unis, 45415
- Dayton Gastroenterology, Inc
-
-
Oregon
-
Portland, Oregon, États-Unis, 97220-9442
- The Oregon Clinic, P.C.
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, États-Unis, 17011
- Susquehanna Research Group, LLC
-
Pittsburgh, Pennsylvania, États-Unis, 15213
- University of Pittsburgh Medical Center Health System
-
Pittsburgh, Pennsylvania, États-Unis, 15212
- Allegheny Center for Digestive Health
-
Uniontown, Pennsylvania, États-Unis, 15401
- Frontier Clinical Research, LLC
-
-
South Carolina
-
Summerville, South Carolina, États-Unis, 29486
- Palmetto Primary Care Physician Division of Gastroenterology
-
-
South Dakota
-
Rapid City, South Dakota, États-Unis, 57701
- Rapid City Medical Center, LLC
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37204
- Vanderbilt University Medical Center
-
-
Texas
-
Austin, Texas, États-Unis, 78712
- The University of Texas at Austin
-
Houston, Texas, États-Unis, 77030
- Baylor College of Medicine
-
Southlake, Texas, États-Unis, 76092
- GI Alliance - Southlake
-
-
Utah
-
Ogden, Utah, États-Unis, 84403
- Care Access Research Berkley
-
Salt Lake City, Utah, États-Unis, 84132
- University of Utah
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- GCGA Physicians LLC
-
Lynchburg, Virginia, États-Unis, 24502
- Gastroenterology Associates
-
-
Washington
-
Bellevue, Washington, États-Unis, 98405
- GI Alliance
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
- Has agreed to use the CDPATH™ tool.
- Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.
Exclusion Criteria:
- Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
- Has had any non-CD-related abdominal surgery.
- Has received investigational biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
- Has previously used CDPATH™ or PROSPECT results to assess CD risk for complications.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: CDPATH™
Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis. |
Crohn's disease risk prediction tool.
Autres noms:
Three blood samples will be drawn. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants in Real-world Practice in Each Risk Category at Baseline Based on the CDPATH™ Tool Results
Délai: Baseline (Day 1)
|
The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years. |
Baseline (Day 1)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants with Specific Treatment Path and Choice Based on CDPATH™ Tool, Stratified According to Risk Category
Délai: Up to 36 months
|
Treatment path (i.e., sequence over time) and choice, by low, medium and high risk, will be chosen to characterize treatment path and choice based on risk stratification. |
Up to 36 months
|
|
Change From Baseline in Decisional Conflict Scale (DCS) Score
Délai: Baseline, then every 6 months up to 36 months
|
DCS is a validated electronic patient-reported outcome (ePRO) collected via electronically administered patient surveys. It measures personal perceptions of the following responses: uncertainty in choosing options, modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making, and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. DCS involves answering 11 questions of PRO, of which 10 questions can be answered as yes (score = 0) or unsure (score = 2) or no (score =4). The total score will range from 0 to 40. Higher score indicates higher decisional conflict. |
Baseline, then every 6 months up to 36 months
|
|
Change From Baseline in Work Productivity and Activity Impairment Questionnaire - CD Version (WPAI-CD) Score
Délai: Baseline, then every 6 months up to 36 months
|
WPAI-CD is a validated ePRO collected via electronically administered patient surveys. It consists of six questions that evaluate 4 domain scores: absenteeism (i.e., work time missed), presenteeism (i.e., reduced work productivity), overall work impairment, and activity impairment. Scores are expressed as a percentage of impairment, where higher scores indicate greater impairment and reduced productivity. The total score ranges from 0 (no impairment) to 100% (total loss of work productivity). |
Baseline, then every 6 months up to 36 months
|
|
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale Score
Délai: Baseline, then every 6 months up to 36 months
|
PROMIS Global Health scale is a validated ePRO collected via electronically administered patient surveys. It is a 10-item PRO measuring the overall evaluation of one's physical and mental health. The total score ranges from 0 to 100. The final score will be represented by the T-score metric, in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A higher PROMIS T-score represents more of the concept being measured (higher Global Health score indicate better health). |
Baseline, then every 6 months up to 36 months
|
|
Patient-Reported Satisfaction and Experience Score with the CDPATH™ Tool
Délai: Up to 36 months
|
Participant's satisfaction and experience with the CDPATH™ tool will be assessed based on 15 questions. Negative responses/lower score to/in these questions indicates less satisfaction whereas positive responses/higher score indicates satisfaction with the tool. |
Up to 36 months
|
|
Number of Participants with Clinical Outcomes
Délai: Up to 36 months
|
Participants with clinical outcomes describing the disease burden based on treatment path and controlling for risk strata will be reported. |
Up to 36 months
|
|
Percentage of Participants with Healthcare Resource Utilization
Délai: Up to 36 months
|
Healthcare resource includes healthcare provider (HCP) visits/referrals, visit to emergency room, hospitalizations, surgery, new CD-related complications, and diagnostic evaluations (e.g., imaging, colonoscopy, etc.). |
Up to 36 months
|
|
Change from First Assessment in Health Care Provider (HCP)-reported Assessment of the Feasibility and Usability of the CDPATH™ Tool
Délai: First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)
|
HCP-reported CDPATH™ satisfaction data will be collected directly from HCPs via electronically administered HCP surveys and entered into the eCRF. HCPs will be queried regarding their satisfaction and experience with the general process, the ease of incorporating the tool in their everyday practice, and the impact of the tool on their treatment recommendations and participant communications. For the 6 questions, HCP will rate on 1-5 scale where, 1=strongly disagree and 5=strongly agree. For remaining 4 questions, written feedback from HCP will be consider. Overall positive responses will indicate higher feasibility and usability. |
First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Study Director, Takeda
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies intestinales
- Maladies du système digestif
- Maladies gastro-intestinales
- Gastro-entérite
- Maladies intestinales inflammatoires
- Maladie de Crohn
- Techniques d'investigation
- Manipulation des échantillons
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Perforation
- Procédures chirurgicales, opératoires
- Collection d'échantillons de sang
Autres numéros d'identification d'étude
- Vedolizumab-4015
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Critères d'accès au partage IPD
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .